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Helicase-like transcription factorIn our study, transcriptome microarrays are used to identify differentially expressed miRNAs and
mRNAs in cervical cancer specimens. We ﬁnd that microRNA-145 (miR-145) expression is signiﬁ-
cantly decreased in cervical cancer tissues and cell lines, and is associated with advanced cancer
stages, large tumor size and moderate/poor differentiation. We show that miR-145 targets the
DNA damage repair-associated gene Helicase-like transcription factor (HLTF), which is involved in
radio-resistance. Moreover, miR-145 over-expression in cervical cancer cells enhances radiosensitiv-
ity in vitro and in vivo. These results indicate that targeting miR-145 may be a novel radiosensitizing
strategy for cervical cancer.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of small non-coding RNAs that
can regulate gene expression through the degradation or transla-
tional inhibition of target mRNAs [1]. An increasing number of
miRNAs has been demonstrated to been involved in the initiation
and progression of various human malignancies [2] and potentially
represent novel diagnostic and prognostic markers [3,4]. Moreover,
recent evidence has linked several miRNAs with treatment
response, such as let-7e [5], miR-375 [6] and miR-200c [7], which
play important roles in radiation or chemotherapy sensitivity.
Cervical cancer is one of the leading gynecological malignancies
worldwide [8]. Previous studies have reported that many miRNAs
can act as oncogenes (e.g., miR-182, miR-205) [9,10] or tumor
suppressors (e.g., miR-7, miR-214) [11,12] in cervical cancer. How-
ever, our understanding of the potential roles of miRNAs in the
prognosis evaluation and treatment response of cervical cancer isstill limited. Combining miRNA expression information with clini-
copathological characteristics and identifying the lead target
mRNAs are helpful in guiding the study of the functions and mech-
anisms of abnormally expressed miRNAs in cervical cancer.
In our study, to screen aberrant miRNAs and predict the corre-
sponding target mRNAs, high-throughput transcriptome micro-
arrays were used to detect differentially expressed miRNAs and
mRNAs synchronously in cervical cancer tissues compared with
adjacent non-tumor tissues. From our microarray results, we
investigated the most signiﬁcantly down-regulated (>4-fold) miR-
NA (Hsa-miR-145-5p, miR-145) in clinical specimens and ana-
lyzed the association between miR-145 expression levels and
speciﬁc clinicopathological characteristics. Then, we combined
microarray analyses and bioinformatic predictions to screen can-
didate target mRNAs of miR-145 effectively and accurately. Heli-
case-like transcription factor (HLTF) was the best candidate target
gene, and it was found to confer radiation resistance in cervical
cancer in a recent study [13]. Moreover, we further demonstrated
that miR-145 over-expression in cervical cancer cells could
enhance radiosensitivity in vitro and in vivo, which showed a
additional anticancer function of miR-145 in cervical cancer.
These ﬁndings might help establish new strategies for therapy
decision-making and improving therapeutic effect of cervical
cancer.
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2.1. Patients and samples
Human cervical tissue samples were collected from patients at
the department of Obstetrics and Gynecology at Changzheng
Hospital (Shanghai, China) between 2012 and 2013. A total of 47
paired cervical cancer tissues and adjacent non-tumor tissues (at
P2 cm from each tumor) were obtained from patients with cervi-
cal cancer (FIGO stage IB-IIB). All patients recruited in this study
were not subjected to preoperative radiotherapy and/or chemo-
therapy. Besides, three normal cervical epithelial tissue samples
were obtained from three premenopausal women (Human papillo-
mavirus negative, HPV) undergoing hysterectomy for myoma.
The collection of human tissue samples was approved and super-
vised by the Ethics Committee of Changzheng Hospital.
2.2. Cell culture and transfection
Human cervical cancer cell lines (HeLa, SiHa, C-33A, Caski) were
obtained from the Cell Bank of Chinese Academy of Science
(Shanghai, China) and maintained as recommended by the Ameri-
can Type Culture Collection (ATCC, USA). Cells were transfected
with miR-145 mimic (RiboBio, China) or miRNA negative control
(miR-NC) using the riboFECT™ CP transfection reagent (RiboBio,
China) according to the manufacturer’s instructions. The ﬁnal con-
centration of either mimic was 50 nM in the cell culture medium.
2.3. Microarray analyses and bioinformatic predictions
Brieﬂy, double-stranded complementary DNA (cDNA) was syn-
thesized from 5 cervical cancer tissues and paired adjacent non-
tumor tissues through reverse-transcription polymerase chain
reactions and then hybridized to Glue Grant Human Transcriptome
arrays (Affymetrix, USA) following the manufacturer’s protocol.
Affymetrix Expression Console Software (version 1.3.1) was used
for microarray analysis. We identiﬁed differentially expressed
genes by the random variance model (RVM) t-test and false discov-
ery rate (FDR) analyses, with a predeﬁned P-value threshold of
<0.05 [14]. Hierarchical clustering (Cluster 3.0) and TreeView anal-
ysis (Stanford University, USA) were performed based on the
results of differentially expressed genes. TargetScan, miRdb and
miRanda combined with the differentially expressed mRNA identi-
ﬁed in the microarray were used to predict the putative targets.
The microarray data discussed in this article have been submitted
to the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) and are accessible through the (GEO)
Series accession number GSE5594 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE55940).
2.4. RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissues or cells using the RNAiso
Plus reagent (Takara, Japan), and cDNA was synthesized using the
SuperScript II Reverse Transcriptase kit (Invitrogen, USA). For
miRNA, RNA was reverse transcribed using a speciﬁc reverse-tran-
scription primer. Quantitative real-time PCR (qRT-PCR) analyses
were performed with SYBR Premix Ex Taq™ (Takara, Japan) using
a StepOne-plus Real-Time PCR system (ABI, USA). U6 snRNA or 18S
rRNA was used as internal controls to normalize the expression
levels of miRNAs or mRNAs, respectively. The relative expression
levels of miRNAs or mRNAs were calculated using the 2DDCt
method. The primers for HLTF mRNA and 18S rRNA were as fol-
lows: HLTF (forward, 50-GAA ATG GAA CCA GCT GAG GCT-30;
reverse, 50-TGT TCC CAG AAT GGT GGA AGT T-30); 18S (forward,50-AAC TGC GAA TGG CTC ATT AAA TC-30; reverse, 50-TTG ATC
TGA TAA ATG CAC GCA TC-30). For miR-145, we used the Bulge-
Loop™ miRNA qRT-PCR Primer Set, including a speciﬁc reverse-
transcription primer and miR-145 forward and reverse primers
(RiboBio, China). The sequences of the primers were not provided
by the manufacturer.
2.5. Vectors construction and Luciferase reporter assays
The 30 untranslated regions (30-UTR) of HLTF mRNA containing
the intact miR-145 recognition sequences were PCR-ampliﬁed
and subcloned into the Sac I and Xba I sites of pmirGLO vector (Pro-
mega, USA) for Luciferase reporter assay. The primer sequences
were as follows: forward, 50-CGA GCT CAG TTG GGA AGT TAC
CTG-30; reverse, 50-GCT CTA GAG AAG GTA ATA AAC ATT TGA
A-30. The pmirGLO-30 UTR with mutations in miR-145 binding sites
was synthesized by GenScript (Nanjing, China). Luciferase assays
were performed in HeLa cells. miR-145 mimic or miR-NC was
co-transfected with pmirGLO-30-UTR vector using the riboFECT™
CP transfection reagent. After a 48-h incubation, ﬁreﬂy and Renilla
luciferase activities were measured with the Dual-Luciferase
Reporter system (Promega, USA) following the manufacturer’s
instructions. Fireﬂy luciferase activity was normalized to Renilla
luciferase activity for each sample.
2.6. Western blot assays
Cells were harvested in RIPA lysis buffer (Beyotime, China).
Equal amounts of protein were separated by SDS–PAGE and trans-
ferred onto polyvinylidene ﬂuoride membranes (Millipore, USA).
The membranes were blocked in phosphate-buffered saline/
Tween-20 containing 5% non-fat milk and incubated with an anti-
body against HLTF or b-actin (Santa Cruz Biotechnology, USA).
Then, the membranes were incubated with HRP-labeled rabbit
anti-goat IgG (KPL, USA) and detected using an Epson Perfection
V300 Photo Scanner (Epson, Japan). Quantitative analysis was per-
formed using AlphaEase FC software (Alpha Innotech, USA). Protein
levels were normalized to b-actin.
2.7. Irradiation
Cells and nude mice were exposed to 60Co-gamma ray irradia-
tion at different doses (dose rate: 1 Gy/min) in the irradiation cen-
ter of the Second Military Medical University (SMMU, Shanghai,
China), depending on the requirements of the experiment [7].
2.8. Cell viability assay
Cells plated at 60–70% conﬂuency in 6-well plates were trans-
fected with miR-145 mimic or miR-NC and incubated for 24 h.
Then, the cells were seeded in 96-well plates (1  104 cells per
well). After overnight incubation, the cells were irradiated at a dose
of 0 Gy or 8 Gy. Then, after incubation for another 24 h, cell viabil-
ity was determined using CCK-8 (Dojindo, Japan) and by measuring
absorbance at 450 nm using an ELx800™ plate reader (BioTek,
USA), following the manufacturer’s instructions.
2.9. Flow cytometric analysis of cell apoptosis
Cells plated at 60–70% conﬂuency in 6-well plates were trans-
fected with miR-145 mimic or miR-NC and incubated for 24 h.
Then, the cells were exposed to 0 Gy or 8 Gy irradiation. At 24 h
after irradiation, the Annexin V-FITC cell apoptosis detection kit
(Beyotime, China) was used to detect apoptotic cells with a MACS-
Quant Analyzers ﬂow cytometer (Miltenyi Biotec, Germany), fol-
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using FlowJo software (Tree Star, USA).
2.10. Tumor xenograft assay
Female nude mice (BALB/C, 5 weeks old) were purchased from
Shanghai Laboratory Animal Center (SLAC, China) and housed
under speciﬁc pathogen-free conditions. All the animal experi-
ments were approved by the Institutional Animal Care and Use
Committee of the SMMU (Shanghai, China). To establish the subcu-
taneous xenograft model, we subcutaneously injected 1  107
HeLa cells in 0.10 ml of phosphate-buffered saline (PBS) into the
right thigh of the nude mice. Ten days after tumor cell inoculation,
the cells formed palpable tumors, and the mice were divided ran-
domly into three groups (four mice per group) for treatment: (1)
2 nmol miR-145 agomir (cholesterol-conjugated 20-O-methyl-
modiﬁed microRNA mimic, RiboBio, China) plus 4 Gy; (2) 5 nmol
miR-145 agomir plus 4 Gy; (3) 2 nmol miR-NC plus 4 Gy. For ago-
mir treatment, miR-145 agomir (RiboBio, China) was directly
injected intratumorally at a dose of 2 nmol or 5 nmol (diluted in
25 lL of PBS) per mouse in the two treatment groups every 4 days
for 6 treatments. miR-NC agomir was directly injected intratumor-
ally at a dose of 2 nmol (diluted in 25 lL of PBS) per mouse in the
control group every 4 days for 6 treatments. All of the mice
received intratumor injection at days 12, 16, 22, 24, 28, 32, and
were exposed to 4 Gy irradiation 24 h after each injection. The
tumors were monitored with calipers, and tumor volumes wereFig. 1. Hierarchical clustering analysis indicates the differentially expressed miRNAs in ce
or green color represents expression values and indicates up- or down-regulation, respe
Fig. 2. MiR-145 expression is decreased in cervical cancer. (A) Signiﬁcant down-regulatio
non-tumor tissues (⁄⁄⁄P < 0.001, n = 42). The relative expression levels of miR-145 were n
cancer cell lines compared with normal cervical epithelial tissues.calculated as length  (width)2/2. At day 34, the mice were sacri-
ﬁced by cervical dislocation. The xenograft tumors were excised
and photographed.
2.11. Statistical analyses
Statistical tests for data analysis includedWilcoxon signed-rank
test, Student’s t-test, the Chi-square test, and Pearson’s coefﬁcient
correlation. The data are presented as the mean ± S.D. A P-
value < 0.05 was considered signiﬁcant. GraphPad Prism5 (Graph-
Pad Software, USA) was used for the statistical analyses.
3. Results
3.1. Microarrays of aberrantly expressed miRNAs and mRNAs in
cervical cancer tissues
To investigate potential transcriptome changes in cervical can-
cer, we performed a gene chip study in ﬁve paired cervical cancer &
adjacent non-tumor tissues using the Affymetrix Human Tran-
scriptome array. There were 4 up-regulated miRNAs (miR-760,
922, 31-5p, 371b-3p), 8 down-regulated miRNAs (miR-145, 27b-
3p, 361-5p, 361-3p, 297, 645, 24-3p, 23b-3p; Fig. 1), and 2189 dif-
ferentially expressed mRNAs (1288 up-regulated, 901 down-regu-
lated; Supplemental Fig. 1) detected in the microarray. The
threshold was a fold change P1.2 with P < 0.05. Among these
results, miR-145 was the most differentially expressed miRNArvical cancer tissues. A heat map shows 12 differentially expressed miRNAs. The red
ctively (c, cancer tissues; ad, paired adjacent non-tumor tissues).
n of miR-145 was observed in cervical cancer tissues compared with paired adjacent
ormalized as ln(2DDCt). (B) The expression of miR-145 was much lower in cervical
Table 1
Clinical characteristics of 42 cervical cancer patients according to miR-145 expression
levels.
Feature miR-145
expression level
Chi-square P value
Low High
All cases 21 21
Age, years, <45:P45 9:12 11:10 0.382 0.537
Tumor size, cm, <4:P4 6:15 14:7 6.109 0.013
FIGO stage, IB:IIA:IIB 4:9:8 12:5:4 6.476 0.039
Degree of differentiation,
highly:moderately:poorly
3:10:8 11:4:6 7.429 0.024
SCC-Ag, ng/ml, <1.5:P1.5 7:14 12:9 2.403 0.121
lymph node metastasis, yes/no 8:13 11:10 0.865 0.352
Hb before treatment, g/L,
<90:90–110:>110
7:8:6 5:9:7 0.469 0.791
Results were considered statistically signiﬁcant at P < 0.05.
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miR-145 is frequently down-regulated and acts as a tumor sup-
pressor in various human malignancies including cervical cancer
[15–18]. Therefore, we chose miR-145 for further investigation of
its signiﬁcance in tumor pathogenesis and clinical treatment.
3.2. Association of miR-145 with the clinicopathological characteristics
of cervical cancer patients
Recent studies have also shown that miR-145 is down-
regulated in cervical cancer; however, the relationship between
miR-145 expression and the clinicopathological characteristics ofFig. 3. HLTF is directly and speciﬁcally suppressed by miR-145. (A) HLTF expression wa
tissues. The relative expression levels of HLTF were normalized as ln(2DDCt). (B) An inve
cancer tissues (n = 42, r = 0.571, P < 0.001). (C) Luciferase activities were assessed 48 h
30UTR and miR-145 mimic or miR-NC in HeLa cells. miR-145 signiﬁcantly repressed the l
times. (D) Wild-type or mutant 30UTR of HLTF, indicating the interaction sites between
signiﬁcantly reduced 48 h after miR-145 mimic or miR-NC transfection in HeLa cells, ascervical cancer patients remains unclear [19,20]. We ﬁrst exam-
ined miR-145 expression levels in another 42 paired cervical can-
cer & adjacent non-tumor tissues by qRT-PCR. The miR-145
expression was lower in cervical cancer tissues compared with
the corresponding adjacent non-tumor tissues (Fig. 2A). Then, we
evaluated the relationship between miR-145 expression and clini-
copathological factors (Table 1). The median miR-145 expression
level in tumor tissues was used as the cutoff. We found that a
lower miR-145 expression was signiﬁcantly more frequent in cer-
vical cancer tumors with advanced stages, large tumor size and
moderate/poor differentiation. Moreover, we found that the
expression of miR-145 was much lower in cervical cancer cell lines
compared with normal cervical epithelial tissues, which further
suggested that the down-regulation of miR-145 was a common
phenomenon in cervical cancer (Fig. 2B).
3.3. HLTF is a direct target of miR-145 in cervical cancer
To determine the potential effects and molecular mechanisms
of down-regulated miR-145 on the malignant behaviors of cervical
cancer cells, we focused on identifying a speciﬁc target gene of
miR-145. We ﬁrst utilized three algorithms (TargetScan, miRdb
and miRanda) combined with the up-regulated mRNAs from the
microarray to predict and analyze the most likely target gene. With
this method, 5 potential target genes were identiﬁed: HLTF, ONE-
CUT2, BCR, NUFIP2, and ZC3H11A. Among these results, HLTF
(GenBank Accession NM_003071.3, transcript variant 1) was the
most signiﬁcantly up-regulated (1.96-fold) mRNA. The qRT-PCR
showed that the HLTF expression was higher in cervical cancer tis-s assessed using qRT-PCR in cervical cancer tissues and paired adjacent non-tumor
rse correlation was found between the levels of miR-145 and HLTF mRNA in cervical
after co-transfection with pmirGLO vector containing the wild-type or mutant HLTF
uciferase activity of the wild-type HLTF 30UTR. All experiments were repeated three
miR-145 and 30UTR of HLTF. (E and F) The mRNA and protein levels of HLTF were
determined by RT-qPCR and Western blotting. ⁄P < 0.05, ⁄⁄P < 0.01.
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(Fig. 3A). Moreover, correlation analysis showed that only HLTF
expression signiﬁcantly inversely correlated with miR-145 in cer-
vical cancer tissues (r = 0.571; Fig. 3B). To determine whether
HLTF is selectively regulated by miR-145, we performed luciferase
reporter assays with the pmirGLO vector carrying the miR-145-
complementary sequence of the wild-type or mutant HLTF 30UTRs
(Fig. 3D). The two vectors were co-transfected with miR-145mimic
or miR-NC into HeLa cells. The luciferase assay results indicated
that luciferase activity was signiﬁcantly repressed by miR-145
and was not affected in the mutant 30UTR group (Fig. 3C). Addition-
ally, HLTF mRNA and protein levels were both inhibited in HeLa
cells transfected with miR-145 mimic (Fig. 3E and F). These results
showed that HLTF was a direct target gene of miR-145 in cervical
cancer.
3.4. Irradiation induces higher miR-145 expression levels in several
cervical cancer cell lines
Because the above results suggested that HLTF was a direct tar-
get gene of miR-145 in cervical cancer cells, we attempted to deter-
mine the potential role of miR-145 in the identiﬁed function and
mechanism of HLTF. In recent years, several studies have demon-
strated that HLTF can act as either a positive or a negative regulator
of tumor development, and it is therefore a controversial molecule
[21–24]. Moreover, a recent study indicated that HLTF is an impor-
tant molecule that inﬂuences the outcome of radiotherapy in cer-
vical cancer [13]. Therefore, we hypothesized that miR-145 may
be associated with radiosensitivity. To test this hypothesis, we ﬁrst
treated several cervical cancer cell lines with increasing doses of
irradiation. Then, RT-qPCR analyses showed that the expressions
of miR-145 were increased after irradiation in HeLa, SiHa and CaskiFig. 4. Radiation induces miR-145 expression in cervical cancer cells. (A–D) The radiati
respectively.⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.cells, but not in C-33A cells (Fig. 4). Because HeLa, SiHa and Caski
cells contain wild-type p53, but C-33A cells harbors mutant p53.
Thus, these results suggested that miR-145 might play a potential
role in modulating the sensitivity of cervical cancer cells to radio-
therapy and relying on wild-type p53.
3.5. miR-145 over-expression enhances radiation-induced cell viability
reduction and apoptosis in cervical cancer cells in vitro
To further investigate whether miR-145 could modulate radio-
sensitivity by regulating HLTF expression in vitro, we ﬁrst exoge-
nously up-regulated miR-145 expression in HeLa and SiHa cells
by transfecting miR-145 mimic (Fig. 5A and B). The CCK-8 assay
and ﬂow cytometric analysis showed that miR-145 mimic could
inﬂuence cell viability and apoptosis level alone but not very
remarkable (Fig. 5C–F, left panel). Nonetheless, radiation-induced
cell viability reduction and cell apoptosis both increased signiﬁ-
cantly by miR-145 mimic (Fig. 5C–F, right panel). These results
suggested that miR-145 could enhance radiosensitivity of cervical
cancer cells.
3.6. Exogenous miR-145 enhances radiosensitivity of cervical cancer
cells in vivo
After validating that miR-145 enhanced radiosensitivity of cer-
vical cancer cells in vitro, we further investigated the radiosensitiz-
ing ability of miR-145 in an animal tumor model. We established a
HeLa cell subcutaneous xenograft tumor model in nude mice. The
mice were treated with irradiation alone (irradiation plus NC ago-
mir) or in combination with the miR-145 agomir. The growth
curves and photo of xenograft tumors showed that the tumors in
the irradiation-alone group grew faster than those in the combina-on-induced expression regulation of miR-145 in HeLa, SiHa, Caski and C-33A cells,
Fig. 5. miR-145 increases radiosensitivity in cervical cancer cells. (A and B) The expression of miR-145 was detected by RT-qPCR at 48 h after miR-145 mimic or miR-NC
transfection in HeLa and SiHa cells. (C and D) At 24 h after transfection, the cells were exposed to 0 Gy or 8 Gy of 60Co-gamma ray irradiation. Then, cell viability was assessed
at 24 h after irradiation. (E and F) At 24 h after transfection, the cells were irradiated with 0 Gy or 8 Gy. Then, the number of apoptotic cells was assayed by ﬂow cytometry
after another 24 h, using PI/Annexin V-FITC double-staining. Representative graphs are shown above (early apoptosis, lower right area; late apoptosis, upper right area).
⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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tion group with the higher dose of miR-145 agomir (Fig. 6A and B).
Additionally, HLTF expression decreased signiﬁcantly in the
corresponding tumor tissues (Fig. 6C). Thus, these results further
demonstrated that miR-145 exerted a radiosensitizing effect on
cervical cancer cells.
4. Discussion
Previous studies has suggested that miR-145 is down-regulated
and acts as a tumor suppressor in various human cancers [25,26].
Recent articles have also reported HPV oncoproteins E6 and
E7 could suppress miR-145 expression [20]. In our study, weconsistently found that miR-145 expression was remarkably
decreased in cervical cancer tissues and cell lines. And our investi-
gation further discovered that decreased miR-145 was signiﬁcantly
associated with clinicopathological features, including advanced
cancer stages, large tumor size and moderate/poor differentiation.
Identifying the lead speciﬁc target mRNA allows us to study the
main functions and molecular mechanisms of miR-145 more effec-
tively. Here, microarray analyses and bioinformatics predictions
showed that HLTF was the top candidate target of miR-145. HLTF,
belongs to the SNF/SWI family, which plays roles in chromatin
remodeling and facilitates trans-factor interactions with nucleo-
somes [27–29]. In our study, we found that HLTF was up-regulated
in cervical cancer tissues and inversely correlated with miR-145.
Fig. 6. miR-145 reduces tumor growth in vivo combined with irradiation. (A) Growth curves of HeLa cell subcutaneous xenograft tumors treated with miR-145 agomir or
miR-NC agomir and irradiation. (B) Mice of different treatment groups were euthanized at days 34 after inoculation, and tumors were excised and photographed. (C) HLTF
expressions in xenograft tumors of different treatment groups. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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could selectively down-regulate HLTF by targeting the 30UTR of
HLTF.
Although several studies have identiﬁed HLTF as a tumor sup-
pressor gene in digestive tract cancers [30,22], a recent article
demonstrated that HLTF confers radio-resistance in cervical cancer
by enhancing DNA damage repair capacity of cancer cells [13]. This
ﬁnding provided us a valuable avenue for further study of the pos-
sible role of miR-145 in the treatment response of cervical cancer.
As expected, our results showed that miR-145 over-expression
enhanced radiosensitivity of cervical cancer in vitro and in vivo
through inhibiting cell viability and increasing radiation-induced
apoptosis probable by down-regulating HLTF. These results con-
ﬁrmed the previous report of the radio-resistance role of HLTF
and showed a additional anticancer function of miR-145 in cervical
cancer.
E6 and E7 are the primary HPV oncoproteins, which mainly
target p53 and pRB, respectively [31]. It is well known that p53
is a genome guardian acts as a tumor suppressor. Radiation-
induced DNA damage could activate p53 and further induce cell
cycle arrest and apoptosis [32]. Precious article demonstrated that
p53 transcriptionally induces the expression of miR-145 [25].
Moreover, wild-type p53 is critical for the expression of miR-
145 in cervical cancer cells [18]. Consistently, we found that radi-
ation had no inducing effect on miR-145 expression in C-33A cells
which harbors mutant p53. Furthermore, according to our ﬁnd-
ings and the conclusions above, we speculated that there might
be a potential cascade reaction regarding miR-145 radiosensitiza-
tion in cervical cancer. The process might consist of: (1) radia-
tion-induced DNA damage activates p53; (2) activated p53induces the expression of miR-145; (3) up-regulated miR-145
repress HLTF, which ultimately contributes to radiosensitizing
effect in cervical cancer cell. Certainly, we need to further study
it to excavate more speciﬁc mechanism of radiosensitizing effect
of miR-145.
In conclusion, our study demonstrates that decreased miR-145
is associated with advanced clinicopathological characteristics of
cervical cancer, and that miR-145 contributes to radiosensitizing
effect. These ﬁndings suggest that miR-145 may be a signiﬁcant
potential biomarker for prognosis evaluation and a novel radiosen-
sitizing target in cervical cancer, which may help establish new
strategies for therapy decision-making and improving therapeutic
effect of cervical cancer.
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